PharmD Info

A forum for Indian Pharmacy Professionals

New to forum? Learn how to post your questions/topics --- Click Here
Its an inter-professional and collaborative learning platform for the doctors and other healthcare professionals to discuss on various healthcare issues and views with pharmacy professionals. Pharmacist also can assist and share your ideas for the better therapeutic outcomes based on clear evidence. E.g: Drug Information, Decision Analysis and EBM.
Forum rules: The contents of the pharmdinfo.com, such as text, graphics, images, and other material contained on the pharmdinfo.com Site ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on the Pharmdinfo.com Site!

If you think you may have a medical emergency, call your doctor or 108 immediately. pharmdinfo.com does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the Site
  • User avatar
#1263
Dermatology
Taltz (ixekizumab); Eli Lilly; For the treatment of plaque psoriasis, Approved March 2016

Family Medicine
Onzetra Xsail (sumatriptan nasal powder) ; Avanir; For the treatment of migraine, Approved January 2016

Hematology
Idelvion (Coagulation Factor IX (Recombinant), Albumin Fusion Protein); CSL Behring; For the treatment of hemophilia B, Approved March 2016

Kovaltry [Antihemophilic Factor (Recombinant)]; Bayer ; For the treatment of hemophillia A, Approved March 2016

Venclexta (venetoclax); AbbVie; For the treatment of chronic lymphocytic leukemia with 17p deletion, Approved April 2016

Hepatology (Liver, Pancreatic, Gall Bladder)
Defitelio (defibrotide sodium); Jazz Pharmaceuticals; For the treatment of hepatic veno-occlusive disease with renal or pulmonary dysfunction following HSCT, Approved March 2016

Zepatier (elbasvir and grazoprevir); Merck; For the treatment of chronic HCV genotypes 1 or 4 , Approved January 2016

Immunology
Descovy (emtricitabine and tenofovir alafenamide); Gilead; For the treatment of HIV-1 infection, Approved April 2016

Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide); Gilead Sciences; For the treatment of HIV-1 as initial therapy, Approved March 2016

Taltz (ixekizumab); Eli Lilly; For the treatment of plaque psoriasis, Approved March 2016

Infections and Infectious Diseases
Anthim (obiltoxaximab); Elusys Therapeutics; For the treatment of inhalational anthrax , Approved March 2016

Descovy (emtricitabine and tenofovir alafenamide); Gilead; For the treatment of HIV-1 infection, Approved April 2016

Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide); Gilead Sciences; For the treatment of HIV-1 as initial therapy, Approved March 2016

Zepatier (elbasvir and grazoprevir); Merck; For the treatment of chronic HCV genotypes 1 or 4 , Approved January 2016

Nephrology
Cabometyx (cabozantinib); Exelixis; For the treatment of advanced renal cell carcinoma, Approved April 2016

Neurology
Briviact (brivaracetam); UCB; For the treatment of partial onset seizures related to epilepsy, Approved February 2016

Nuplazid (pimavanserin); Acadia Pharmaceuticals; For the treatment of hallucinations and delusions associated with Parkinson’s disease, Approved April 2016

Onzetra Xsail (sumatriptan nasal powder) ; Avanir; For the treatment of migraine, Approved January 2016

Oncology
Cabometyx (cabozantinib); Exelixis; For the treatment of advanced renal cell carcinoma, Approved April 2016

Venclexta (venetoclax); AbbVie; For the treatment of chronic lymphocytic leukemia with 17p deletion, Approved April 2016

Pediatrics/Neonatology
Kovaltry [Antihemophilic Factor (Recombinant)]; Bayer ; For the treatment of hemophillia A, Approved March 2016

Pulmonary/Respiratory Diseases
Bevespi Aerosphere (glycopyrrolate and formoterol fumarate); AstraZeneca; For the treatment of chronic obstructive pulmonary disease, Approved April 2016

Cinqair (reslizumab); Teva Pharmaceuticals; For the treatment of severe asthma, Approved March 2016
Similar Topics
Topics Statistics Last post
New drugs approved by the FDA in 2016
by Admin  - 19 Aug 2016, 12:44  - In: Pharmacy Education
1 Replies 
1239 Views
by Atul
19 Aug 2016, 13:38
22 approved novel drugs in 2016
by Admin  - 09 Feb 2017, 11:11  - In: Pharmacy Education
0 Replies 
940 Views
by Admin
09 Feb 2017, 11:11
0 Replies 
7432 Views
by Admin
23 Oct 2016, 17:58
0 Replies 
459 Views
by Admin
05 Oct 2017, 07:02
0 Replies 
975 Views
by Admin
18 Feb 2017, 10:38

Tags

CDER Drug Safety Priorities 2017 illustrates the m[…]

Top 20 Indian PCD Pharmaceutical Companies

Visit the top Allopathic Pharma Franchise Opportu[…]

Dear Sir/Madam, Bioclinica would like to conduct […]

Miss Madana, We share only the job alerts, try t[…]

WELCOME TO OUR E-LEARN COURSE WORK MODULES